2016 WHO classification incorporate IDH mutation and 1p/19q codeletion status to further classified WHO II/III glioma into three molecular subtypes: IDH‐wildtype, IDH‐mutant and 1p/19q intact, and IDH‐mutant and 1p/19q codeleted.3 The gene discussed is IDH2; the disease is central nervous system cancer.